- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04451135
CET- REM (Correlating ECT Response to EEG Markers)
December 23, 2025 updated by: Washington University School of Medicine
Correlating Electroconvulsive Therapy Response to Electroencephalographic Ictal Complexes and Postictal Markers
Single-center study to determine the relationship between changes in depression symptoms and electroencephalographic (EEG) patterns induced by electroconvulsive therapy (ECT)
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Electroconvulsive therapy (ECT) is an effective treatment for many psychiatric illnesses, including major depressive disorder.
While effective, objective markers have not been developed to predict clinical outcome trajectories following ECT.
This is important given the risks and costs incurred during a full treatment course.
Electroencephalography (EEG) is typically employed to monitor the generation and termination of ECT-induced seizures but leverage of markers toward prognostication remains a future goal.
The investigators have characterized two distinct EEG patterns associated with ECT-induced generalized seizures and have two sleep markers that may serve as markers for predicting response to treatment.
Central Positive Complexes (CPCs) are large ictal complexes with a scalp topology of voltage declining from the top of the head.
CPCs are localized to cortical areas that are involved in the formation of sleep spindles and slow wave sleep.
A pattern of low-voltage activity, known as post-ictal generalized electroencephalographic suppression (PGES), is frequently used to document termination of these seizures.
Additionally, two EEG markers of sleep microstructure may have utility given their association with synaptic plasticity, a process presumably invoked over the course of ECT-induced recovery from psychiatric illness as pathologic neural circuitry undergoes reconfiguration.
These two markers, sleep spindles and slow waves show altered expression patterns in patients with psychiatric disorders, and thus may be useful as objective markers of ECT responsiveness.
None of the above EEG markers have been explored for an association to interval changes in disease severity over the course of ECT.
This project will incisively probe the relationships between temporal trajectories of major depressive disorder severity and longitudinal measurements of ictal and postictal EEG markers.
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Washington University School of Medicine/Barnes-Jewish Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18 years or greater
- Referral for ECT index course for treatment-resistant depression (unipolar major depressive disorder or bipolar depression), major depressive disorder with psychotic symptoms, schizophrenia or schizoaffective being treated for a depressed episode, unspecified depression
Exclusion Criteria:
- Schizophrenia or schizoaffective disorder not being treated for a depressed episode.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Patients with Treatment-Resistant Depression
|
EEG on nights after ECT session will be recorded using the DREEM device.
Sleep EEG data will also be acquired for a minimum of one night prior to the first ECT session, providing a true baseline measure.
The DREEM device allows continuous recording of multichannel EEG
The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) is a measure of depression symptom severity that has been validated for clinical and research use53.
It is a standard self-report measurement completed by patients prior to each ECT session
A high-density 65-electrode EEG scalp electrode net (EGI/Philips) with Elefix conductive gel injected within Ag/AgCl electrode sensors is utilized to monitor brain activity during the ictal period
A board-certified epileptologist will review all seizures to assess seizure parameters, including duration of seizure and interval of PGES.
Preprocessing of the PGES periods will be accomplished with band-pass filtering from 2 to 30 Hz with 1st order Butterworth filters.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Interval change in Quick Inventory of Depressive Symptomatology-16 Item Self Report (QIDS-SR16) between ECT sessions.
Time Frame: Up to 8 weeks during patients ECT treatment course
|
16 item Self-report questionnaire that best describes the participant's depressive symptoms over the last seven days.
Scale: 0=never or do not, 3=nearly all the time, or the highest level of time listed on the question.
|
Up to 8 weeks during patients ECT treatment course
|
|
Duration of Central Positive Complexes during ECT treatments.
Time Frame: Up to 8 weeks during patients ECT treatment course
|
Total time (in seconds) during the ictal period for which CPCs are present in the EEG immediately following seizure induction until termination of the seizure. Range of values: 0 - 300 seconds |
Up to 8 weeks during patients ECT treatment course
|
|
Duration of PGES during ECT treatments.
Time Frame: Up to 8 weeks during patients ECT treatment course
|
Total time (in seconds) during the postictal period for which PGES is present in the EEG immediately following seizure termination for up to 5 minutes. Range of values: 0 - 300 seconds |
Up to 8 weeks during patients ECT treatment course
|
|
Density of EEG sleep spindles during non-rapid eye movement (NREM) stages N2 on evenings following ECT treatments.
Time Frame: Up to 8 weeks during patients ECT treatment course
|
The total number of EEG sleep spindles per minute present during N2 sleep.
Range of values: 0 - 60 spindles/min
|
Up to 8 weeks during patients ECT treatment course
|
|
Slow wave activity (SWA) during N3 sleep on evenings following ECT treatments
Time Frame: Up to 8 weeks during patients ECT treatment course
|
Total power of EEG slow waves per minute present during the first identified cycle of N3 sleep Range of values: 0 - 50 dB/min
|
Up to 8 weeks during patients ECT treatment course
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: MohammadMehdi Kafashan, Washington University School Of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Lopez J, Hoffmann R, Armitage R. Reduced sleep spindle activity in early-onset and elevated risk for depression. J Am Acad Child Adolesc Psychiatry. 2010 Sep;49(9):934-43. doi: 10.1016/j.jaac.2010.05.014. Epub 2010 Jul 24.
- Kho KH, van Vreeswijk MF, Simpson S, Zwinderman AH. A meta-analysis of electroconvulsive therapy efficacy in depression. J ECT. 2003 Sep;19(3):139-47. doi: 10.1097/00124509-200309000-00005.
- Kafashan M, Brian Hickman L, Labonte AK, Huels ER, Maybrier H, Guay CS, Subramanian S, Farber NB, Ching S, Hogan RE, Kelz MB, Avidan MS, Mashour GA, Palanca BJA. Quiescence during burst suppression and postictal generalized EEG suppression are distinct patterns of activity. Clin Neurophysiol. 2022 Oct;142:125-132. doi: 10.1016/j.clinph.2022.07.493. Epub 2022 Jul 30.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 9, 2020
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
June 1, 2027
Study Registration Dates
First Submitted
June 24, 2020
First Submitted That Met QC Criteria
June 26, 2020
First Posted (Actual)
June 30, 2020
Study Record Updates
Last Update Posted (Actual)
December 31, 2025
Last Update Submitted That Met QC Criteria
December 23, 2025
Last Verified
December 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202006108
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Treatment Resistant Depression
-
Sunnybrook Health Sciences CentreRecruitingTreatment-Resistant Depression | Treatment-resistant Depression (TRD)Canada
-
NeuroRx, Inc.neurocare group AG; Zeta Surgical, Inc.; HOPE Therapeutics, Inc.Not yet recruitingTreatment Resistant Depression | Treatment Resistant Depression (TRD)United States
-
Changping LaboratoryBeijing HuiLongGuan HospitalSuspendedTreatment-Resistant DepressionChina
-
Washington University School of MedicineNational Institute of Mental Health (NIMH)CompletedTreatment-resistant DepressionUnited States
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
University Hospital FreiburgBoston Scientific CorporationCompletedTreatment-resistant DepressionGermany, France
-
Centre for Addiction and Mental HealthCompletedTreatment-resistant DepressionCanada
-
Janssen Research & Development, LLCCompletedTreatment-resistant DepressionUnited States, Australia, France, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Poland, Bulgaria, Malaysia, South Africa, Turkey, Finland, Korea, Republic of, Brazil, Austria, Sweden, Lithuania
-
Janssen Research & Development, LLCCompletedTreatment-resistant DepressionUnited States, France, Belgium, Mexico, Canada, Brazil, Estonia, Hungary, Slovakia
-
Central Institute of Mental Health, MannheimCharite University, Berlin, Germany; German Federal Ministry of Education and... and other collaboratorsCompletedTreatment-resistant DepressionGermany
Clinical Trials on Electroencephalographic (EEG)
-
L. Eugene ArnoldNational Institute of Mental Health (NIMH); Brain Resource CenterCompletedAttention Deficit Hyperactivity DisorderUnited States
-
HealthTech Connex Inc.Terminated
-
Rennes University HospitalFondation de l'AvenirRecruitingStroke | Brain Infarction | Stroke, Ischemic | Stroke Hemorrhagic | Stroke RehabilitationFrance
-
Tanta UniversityCompletedCraving | Electroencephalographic | Biofeedback Therapy | HeroinEgypt
-
University of MiamiRecruitingSpinal Cord Injury (SCI), Initial EncounterUnited States
-
University Hospital, BordeauxCompletedTourette SyndromeFrance
-
Epiminder America, Inc.RecruitingEpilepsy | Epilepsy (Treatment Refractory)United States
-
National Taiwan University HospitalRecruiting
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Epiminder America, Inc.RecruitingEpilepsy | Epilepsy (Treatment Refractory)United States